Source briefingAugust 24, 2026Health & Science
Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Date of authorisation: 10/04/2017, Revision: 8, Status: Authorised

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.
What the source reports
Human medicines European public assessment report (EPAR): Chenodeoxycholic acid Leadiant (previously Chenodeoxycholic acid sigma-tau), chenodeoxycholic acid, Date of authorisation: 10/04/2017, Revision: 8, Status: Authorised
Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.
Source & verification
Primary source: What's new · August 24, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

US Tries but Fails to Dilute UN Human Rights Resolutions
US Attempts to Weaken UN Human Rights Resolutions: An Evidence Review What is established In late 2026, during sessions of the United Nations General…

Medical device makers have gotten worse at disclosing when their products harm people, new study finds. The FDA let them.
What is established A recent peer-reviewed study published in The BMJ and reported by the International Consortium of Investigative Journalists (ICIJ) reveals a decline…

EMA/PE/0000181364
What is established The European Medicines Agency (EMA) has granted a decision regarding a paediatric investigation plan (PIP) for vosoritide as of 8 August…